Non-HPV In-Field Second Primary Squamous Cell Cancers in the HPV De-Escalation Quarterback Trials
Clinical trials evaluating treatments for HPV oropharynx cancer select patients by p16 status rather than molecular identification of HPV and HPV genotype. It is unclear whether recurrences in these trials are tested for HPV either by p16 status or molecular HPV testing. Applying molecular diagnostics for HPV at diagnosis and relapse can avoid significant miss-assignment and inaccurate results. We reviewed and report results from the Quarterback Trials (QT) where we used molecular testing to assign HPV status to all patients at diagnosis and relapse.
Source: International Journal of Radiation Oncology * Biology * Physics - Category: Radiology Authors: M. Posner, W.H. Westra, S. Roof, R.L. Bakst, K. Sindhu, E. Genden, T. Chen, M. Dougherty, D.K. Misiukiewicz Tags: 170 Source Type: research
More News: Biology | Cancer | Cancer & Oncology | Clinical Trials | Molecular Biology | Oropharyngeal Cancer | Physics | Radiology | Squamous Cell Carcinoma